Cardiology - Medtelligence

1-16 of 117

NEW EPISODE
Safety in oHCM Therapy: How and When to Transition Treatment?
Safety in oHCM Therapy: How and When to Transition Treatment?
MinuteCE®
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
1.00 program credit
- Anjali Owens, MD
1.00 program credit
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
- Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- Joseph Rossano, MD
Cracking the Code of Obstruction: Unmet Needs in oHCM
Cracking the Code of Obstruction: Unmet Needs in oHCM
MinuteCE®
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
1.00 program credit
- Michael Nassif, MD, MSc
1.00 program credit
MinuteCE®
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS; Michael Nassif, MD, MSc
1.00 credit 7 episodes
- Ahmad Masri, MD, MS
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 credit 7 episodes
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
Molecular Precision: How Myosin Inhibitors Redefine Control
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®
Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS; Anjali Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
MinuteCE®
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Ahmad Masri, MD, MS; Anjali Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS; Anjali Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
CME/CE
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA; Nihar R. Desai, MD, MPH
0.25 credits
- Ellie Kelepouris, MD, FACP, FAHA
- Nihar R. Desai, MD, MPH
0.25 credits
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Cardiology
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
- Roxana Mehran, MD, FSCAI
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Cardiology
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
- Pam R. Taub, MD, FACC, FASPC
Future Directions in Managing Hyperkalemia in CKD and HF
Future Directions in Managing Hyperkalemia in CKD and HF
MinuteCE®
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA; James Burton, DM, FRCP
1.00 program credit
- Javed Butler, MD, MPH, MBA
- James Burton, DM, FRCP
1.00 program credit
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
MinuteCE®
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
James Burton, DM, FRCP; Patrick Rossignol, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Patrick Rossignol, MD, PhD
1.00 program credit

Prev
1
2
3
…
7
8
Next

1/6